Physician profile
Hee Oh
NPI 1225106693
$5,015.68
in general payments reported to CMS, 2019-2025
15 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $472 · 2021: $629 · 2022: $537 · 2023: $1,033 · 2024: $1,231 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,664.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,481.42 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $645.35 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $423.14 | 2019-2025 | |
| Amarin Pharma, INC. | $308.31 | 2021-2023 | |
| Amgen INC. | $196.31 | 2021-2024 | Evenity, Prolia |
| Nestle Healthcare Nutrition INC. | $148.77 | 2021-2023 | |
| Glaxosmithkline, LLC. | $142.76 | 2023 | Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.49 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Aimmune Therapeutics, INC. | $121.15 | 2024-2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.76 | 2020-2022 | |
| Novo Nordisk INC | $87.68 | 2020-2025 | Ozempic, Rybelsus |
| Roche Diagnostics Corporation | $40.38 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $40.13 | 2023-2025 | Seglentis, Zoryve |
| Sumitomo Pharma America, INC. | $26.03 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hee Oh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.